These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 30603906)

  • 1. Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status.
    Omarini C; Bettelli S; Caprera C; Manfredini S; Barbolini M; Moscetti L; Isca C; Toss A; Barbieri E; Cortesi L; Kaleci S; Maiorana A; Tazzioli G; Cascinu S; Piacentini F
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):821-828. PubMed ID: 30603906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients.
    Omarini C; Bettelli S; Caprera C; Manfredini S; Caggia F; Guaitoli G; Moscetti L; Toss A; Cortesi L; Kaleci S; Maiorana A; Cascinu S; Conte PF; Piacentini F
    Cancer Biol Ther; 2018; 19(10):879-886. PubMed ID: 30067438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.
    Creighton CJ; Hilger AM; Murthy S; Rae JM; Chinnaiyan AM; El-Ashry D
    Cancer Res; 2006 Apr; 66(7):3903-11. PubMed ID: 16585219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic implications of receptor discordance between primary and recurrent breast cancer.
    Matsumoto A; Jinno H; Murata T; Seki T; Takahashi M; Hayashida T; Kameyama K; Kitagawa Y
    Int J Clin Oncol; 2015 Aug; 20(4):701-8. PubMed ID: 25348193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer.
    Lee HJ; Park IA; Park SY; Seo AN; Lim B; Chai Y; Song IH; Kim NE; Kim JY; Yu JH; Ahn JH; Gong G
    Breast Cancer Res Treat; 2014 Jun; 145(3):615-23. PubMed ID: 24820412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
    Linardou H; Kalogeras KT; Kronenwett R; Alexopoulou Z; Wirtz RM; Zagouri F; Scopa CD; Gogas H; Petraki K; Christodoulou C; Pavlakis K; Koutras AK; Samantas E; Patsea H; Pectasides D; Bafaloukos D; Fountzilas G
    Anticancer Res; 2015 Jul; 35(7):4023-36. PubMed ID: 26124351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features.
    Ning SF; Li JL; Luo CP; Wei CH; Lu YK; Liu HZ; Wei WE; Zhang LT
    Int J Clin Exp Pathol; 2014; 7(12):8740-7. PubMed ID: 25674240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer.
    Yanai A; Inoue N; Yagi T; Nishimukai A; Miyagawa Y; Murase K; Imamura M; Enomoto Y; Takatsuka Y; Watanabe T; Hirota S; Sasa M; Katagiri T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):197-203. PubMed ID: 25600244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy.
    Strasser-Weippl K; Horick N; Smith IE; O'Shaughnessy J; Ejlertsen B; Boyle F; Buzdar AU; Fumoleau P; Gradishar W; Martin M; Moy B; Piccart-Gebhart M; Pritchard KI; Lindquist D; Rappold E; Finkelstein DM; Goss PE
    Breast Cancer Res; 2015 Apr; 17(1):56. PubMed ID: 25888246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
    Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups.
    Yao K; Goldschmidt R; Turk M; Wesseling J; Stork-Sloots L; de Snoo F; Cristofanilli M
    Breast Cancer Res Treat; 2015 Nov; 154(1):81-8. PubMed ID: 26424167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and activation of P38 MAP kinase in invasive ductal breast cancers: correlation with expression of the estrogen receptor, HER2 and downstream signaling phosphorylated proteins.
    Merlin JL; Harlé A; Lion M; Ramacci C; Leroux A
    Oncol Rep; 2013 Oct; 30(4):1943-8. PubMed ID: 23900300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
    Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors influencing the hormone receptor and HER2 levels in breast cancer: a population-based analysis.
    Tas F
    Onkologie; 2012; 35(3):95-8. PubMed ID: 22414972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormone receptor and human epidermal growth factor receptor 2 status evaluation on ThinPrep specimens from breast carcinoma: correlation with histologic sections determination.
    Pegolo E; Machin P; Riosa F; Bassini A; Deroma L; Di Loreto C
    Cancer Cytopathol; 2012 Jun; 120(3):196-205. PubMed ID: 22298467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer.
    Roepman P; Horlings HM; Krijgsman O; Kok M; Bueno-de-Mesquita JM; Bender R; Linn SC; Glas AM; van de Vijver MJ
    Clin Cancer Res; 2009 Nov; 15(22):7003-11. PubMed ID: 19887485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear Gli1 expression is associated with pathological complete response and event-free survival in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant therapy.
    Liu S; Duan X; Xu L; Ye J; Cheng Y; Liu Q; Zhang H; Zhang S; Zhu S; Li T; Liu Y
    Tumour Biol; 2016 Apr; 37(4):4873-81. PubMed ID: 26526577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.